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MR Evaluation of Radiation Synovectomy of
the Knee by Means of Intra-articular
Injection of Holmium-166-Chitosan
Complex in Patients with Rheumatoid
Arthritis: Results at 4-month Follow-up
Objective: To determine whether MRI is able to demonstrate the effect of radi-
ation synovectomy after the intra-articular injection of holmium-166-chitosan com-
plex for the treatment of rheumatoid arthritis of the knee. 
Materials and Methods: Fourteen patients aged 36 59 years were treated
with 10 20 mCi of holmium-166-chitosan complex. A criterion for inclusion in this
study was the absence of observable improvement after 3- or more months of
treatment of the knee with disease-modifying anti-rheumatic drugs. MR images
were acquired both prior to and 4-months after treatment. Clinical evaluation
included the use of visual analog scales to assess pain, and the circumference of
the knee and its range of motion were also determined. MR evaluation included
measurement of the volume of synovial enhancement and wall thickness, the
amount of joint effusion, and quantifiable scoring of bone erosion, bone edema
and lymph nodes. 
Results: Visual analog scale readings decreased significantly after radiation
synovectomy (p < 0.05). MRI showed that joint effusion decreased significantly (p
< 0.05), and that the volume of synovial enhancement tended to decrease, but to
an insignificant extent (p = 0.107). 
Conclusion: The decreased joint effusion noted at 4-month follow-up resulted
from radiation synovectomy of the rheumatoid knee by means of intra-articular
injection of holmium-166-chitosan complex.
heumatoid arthritis (RA) is a chronic, progressive, inflammatory joint dis-
order, the primary treatment for which consists of medical regimens aimed
at controlling synovial inflammation of the joint. The key to successful
treatment is to begin with a program of broad therapy early in the disease, and in most
patients, RA can in this way be satisfactorily controlled (1). When medical regimens
have proven unsuccessful, however, surgical synovectomy has traditionally been the
treatment of choice. The procedure remains, though, highly controversial (2): it is, for
instance, technically difficult, if not impossible, to remove all the diseased synovium lin-
ing the joint, and alternative methods of treatment are therefore desirable. 
One such method is radiation synovectomy, involving a radiopharmaceutical injec-
tion into the joint. Its intention is to destroy the inflamed synovium, in the expectation
that the regenerated synovium will be disease-free and the symptoms will thereby be
alleviated. The radiopharmaceuticals most commonly used have been inorganic col-
loids, but leakage of these from the joint has sometimes led to exposure of the liver,
spleen and lymph nodes to radiation (3). Recent advances in radiopharmaceutical de-
sign and synthesis could, however, eventually lead to a new class of radiation synovec-
tomy agents which will exhibit minimal leakage of radioactivity from the treated joint
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R(4, 5). Leakage has been particularly difficult to quantify
where the isotope used was 
90Y or 
32P, radioisotopes which
are both pure beta emitters with no accompanying gamma
emissions that might be used to quantify biodistribution
and dosimetry (6). In contrast to pure beta ray emitters,
166Ho has a number of physical characteristics which make
it suitable for internal radiation therapy; these include an
appropriate half-life (27 hrs), high beta-energy, and low
gamma-energy that permits the use of a gamma camera to
monitor its distribution in the body (7).
Evaluations of the therapeutic effects of radiation syn-
ovectomy in RA cases are generally based upon improve-
ments in measurable patient parameters, namely range of
joint motion, extent of knee effusion, degree of crepitus,
circumference of the knee at midpatella, and pain, and in
recent years, MRI has been used to more objectively assess
these effects (8 15). Measurements of synovial volume,
synovial thickness, and jont effusion obtained at MRI have
shown close correlation with the findings of clinical evalua-
tion (8).
The purpose of this study was to determine whether MRI
is able to demonstrate the effects of radiation synovectomy
after the intra-articular injection of holmium-166-chitosan
complex (
166Ho-CC) for the treatment of RA of the knee.
MATERIALS AND METHODS
Patient selection 
A total of 14 female patients aged 35 59 years, treated
between January and April 1999, were included in this
study. All fulfilled the American College of Rheumatology
(ACR) criteria (16), and the mean duration of their RA was
71.6 months. A criterion for inclusion in this study was a
lack of clinical improvement after 3-or more months of
treatment with disease-modifying anti-rheumatic drugs.
Patients were excluded if they had undergone knee surgery
or if laboratory studies revealed renal, hepatic or hemato-
logical abnormalities. During the follow-up period, medica-
tion was maintained, without dosage change, and the effect
of the medicines used thus did not influence our findings.
This study was approved by the Ethics Subcommittee of
our hospital, and written informed consent was obtained
from each patient prior to their enrollment. 
Characteristics of 
166Ho-CC
166Ho is a product of the neutron activation of holmium-
165, and is predominantly a beta-emitter (Emax = 1.84
MeV) with radiotherapeutic properties appropriate for
therapy. It also emits gamma-ray photons (81 keV, 6.2%),
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Table 1. Clinical Data Obtained Before and After Radiation Synovectomy
Patient No. VAS Knee Circumference (cm) R.O.M.-Flexion ( ) R.O.M.-Extension ( )
T0 T1 T0 T1 T0 T1 T0 T1
015 0 06 37 37.5 65 60 165 165
02 45 21 43.5 39.5 54 65 175 165
03 90 73 34 32.5 60 58 175 169
04 21 16 35 34 40 60 165 180
05 54 34 36.5 36 60 55 175 168
06 60 19 34 34.2 60 58 170 165
07 35 27 40.5 38.5 60 70 175 170
08 68 73 39 37.5 70 60 165 165
09 71 30 34 35.5 60 70 160 161
10 29 50 32.5 32 60 60 175 175
11 61 39 38.5 37.8 60 60 160 165
12 75 56 33 33.7 60 72 170 155
13 78 74 33.5 31.8 60 60 160 160
14 45 07 34.5 34.2 60 55 170 170
Mean 55.9 37.5 36.1 35.3 59.2 61.6 168.6 166.6
SD 19.8 24.1 03.2 02.5 06.5 05.5 006.0 006.2
p value 0.003 0.054 0.311 0.329
Note. VAS: visual analog scale
T0: before treatment
T1: after treatment
R.O.M.: range of motion
SD: standard deviationdetectable at scintillation imaging. Holmium solution (
166Ho
(NO3)3 5H20) was generated at the Korea Atomic Energy
Research Institute (Taejon, Korea). In this study, we used
166Ho-CC, a combination of 
166Ho and chitosan. The latter is
a polymer of 2-deoxy-2-amino-D-glucose with  -1, four
bonds, derived by the deacetylation of chitin (17), and was
supplied by Pharmaceutical Development Lab (Dong Wha
Pharm. Ind. Co. Ltd., Kyunggi-do, Korea). 
166Ho-CC was
injected into the knee joint via the medial or lateral routes
of the suprapatellar recess after the aspiration of 1 2 mL
of joint fluid. The injection volume and dose were approxi-
mately 1 mL and 10 20 mCi, respectively.
MR Imaging Protocol
For all examinations, a 1.5-T MR imaging system (Sigma,
GE Medical Systems, Milwaukee, Wis., U.S.A.) was used.
Images were obtained both before and four months after
the treatment of synovitis of the knee, and the following
pulse sequences were used : (a) T2-weighted spin echo
sagittal imaging (TR/TE=2000/70, FOV=16 16, slice
thickness=4 mm with 1mm interslice gap, matrix=256
256, 1 NEX); (b) T1-weighted spin-echo axial imaging
(TR/TE=620 450/14, FOV=16 16, slice thickness=4
mm with 1 mm interslice gap, matrix=256 192, 1 NEX);
(c) fat-suppressed, three-dimensional spoiled gradient-echo
(3D SPGR) sagittal imaging, both pre- and post-Gd-DTPA
enhancement (TR/TE=21.0-23.6/2.1 3.0, FOV=16 16
to 20 20, slice thickness=1.3 1.5 mm, matrix=256
256, 1 NEX, flip angle=15).
Clinical Evaluation
All clinical evaluations were performed before and 4
months after radiation synovectomy. To assess knee pain,
visual analog scales were used. The system, involving a
form of cross-modality matching in which line length is the
response continuum, is useful for the measurement of
chronic pain (18), and has been reported to provide valid
and reliable measurements of its intensity (19 21). The
circumference of the knee at the level of the center of the
patella was measured before and 4-months after radiation
synovectomy for the evaluation of swelling, and the range
of motion of the knee joint was also evaluated by measur-
ing the angle of flexion and extension using a goniometer. 
Extra-articular leakage of injected 
166Ho-CC was evaluat-
ed in nine patients. For the analysis of gamma-scan images
and radionuclide preparations, counts were corrected for
the decay of 
166Ho to the planned time of evaluation, based
on the half-life of 
166Ho. Whole-body scans were obtained
using a Genesys gamma camera (ADAC, Milpitas, U.S.A.)
with a high-energy collimator. The biodistribution of the
injected DW-166HC was analyzed chronologically by cal-
culating the activity counts of different regions of interest,
including the knee, brain, chest and abdomen. Whole-
body scans were obtained 24 hours and 8 days after injec-
tion.
MR Evaluation
The degree of synovial enhancement was determined
from sagittal fat-suppressed 3D SPGR images (Fig. 1), us-
ing Scion Image (free software developed at the U.S.
National Institutes of Health and modified at the Scion
Corporation). Synovial enhancement volume was decided
by means of the following three steps, as described previ-
ously (8, 9, 22, 23) : first, a region containing synovium
was traced manually; second, a segmentation procedure
was undertaken, threshold cut-off value being defined as
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Fig. 1. MR images of a 50-year-old
woman with rheumatoid arthritis of the
knee.
A. Postcontrast fat-suppressed, three-di-
mensional spoiled gradient-echo sagittal
image (TR/TE=21.1/2.2, flip angle=15 )
shows a highly enhanced pannus (ar-
rowheads). Joint effusion (arrow) is
seen, with low signal intensity at the
suprapatellar recess before treatment in-
volving the intra-articular injection of
166Ho-chitosan complex. 
B. MR image obtained four months after
treatment shows that the size of the
pannus and joint effusion have de-
creased.
ABthe midpoint between the mean voxel value of the enhanc-
ing synovium minus 2 standard deviations (SD) and the
mean voxel value of muscle plus 2 SDs, and mean values
and SDs were obtained from multiple regions of interest;
third, enhanced pixels on a segmented image were count-
ed, and the volume was calculated. These three steps were
repeated for all sagittal images relating to each patient. 
Using sagittal T2-weighted images, synovial thickness
was measured and summed from 18 areas of the suprap-
atellar pouch; anterior and posterior synovial pouch tissue
was divided into midline, lateral and medial regions and
then subdivided into superior, middle and inferior por-
tions. 
The amount of joint effusion was measured on T2-
weighted images, where joint effusion is easily demarcated
from the synovium. Using Scion Image, joint effusion was
determined through three separate steps, identical to the
method mentioned above. Threshold signal intensity was
defined as the midpoint between the mean voxel value of
the joint effusion minus 2 SDs and the mean voxel value of
fat plus 2 SDs. In contrast to the evaluation of synovial en-
hancement, fat was selected as the comparison value due
to its intermediate signal intensity on T2-weighted images.
The volume of any Baker cyst present was measured using
the same method.
Two radiologists (S.H.L, J.S.S) reviewed the MR images
and reached their conclusions by consensus. T1-weighted
axial and 3D SPGR images were used to determine the
number of marginal and central erosions that involved the
medial and lateral femur, medial and lateral tibia, patella,
and tibio-fibular joint (Fig. 2). A lesion was defined as bone
marrow edema if T2-weighted and 3D-SPGR images
showed that it was poorly defined and demonstrated high
signal intensity. If consecutive images indicated that a
nodular lesion present in the popliteal space lacked conti-
nuity to popliteal vessels, it was regarded as a lymph node.
The following scores were assigned: if one or more lesions
were present at each site: 1; if the lesion was aggravated:
1.5; if the lesion had disappeared: 0; and if the lesion was
newly developed: 1. The sum of the scores was obtained
on every occasion.
Statistical Analysis
Spearman s correlation coefficient analysis was used to
assess differences between the visual analog scale readings
obtained before and after radiation synovectomy, and dif-
ferences in MRI findings. The paired t test was used to de-
termine correlation between pre- and post-radiation syn-
ovectomy MR scores and clinical data. The reproducibility
of the quantification of volume measurement was evaluat-
ed, intra- and inter-observer variation being expressed as
mean percentage average absolute variation and percent-
age coefficient of variation. A Statistical Analysis System
package (SPSS version 10.0) was used, and a p value of
<0.05 was considered statistically significant.
RESULTS
Between pre- and post-radiation synovectomy, a signifi-
cant decrease in the visual analog scale was noted [20.1
20.7 (range,  21 to 44)] (p < 0.05). Knee circumference
decreased by 0.8 (range,  1.5 to 4.0) cm (p = 0.054), but
the range of motion of the knee joint was unchanged (p >
0.1). In nine of the 14 patients, synovial enhancement was
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Fig. 2. MR images of a 37-year-old
woman with rheumatoid arthritis of the
knee. 
A. Postcontrast, fat-suppressed, three-
dimensional spoiled gradient-echo sagit-
tal image (TR/TE=21.1/2.2, flip an-
gle=15 ) obtained before the intra-artic-
ular injection of 
166Ho-chitosan complex
depicts extensive bone marrow edema
in the lateral condyle of the femur and
tibia (arrows). Enhanced synovial tissue
is seen in the infrapatellar region and
posterior joint space (arrowheads), and
in the suprapatellar pouch, joint effusion
is apparent (double arrow). 
B. MR image obtained four months after
treatment shows that bone marrow ede-
ma has almost disappeared. Bony ero-
sion still remains, however, and is clear-
ly demarcated in the subchondral bone
of the lateral tibia (arrow). Joint effusion
and the size of the pannus have both
decreased. 
ABreduced (Fig. 1), and in five it had increased (Fig. 3), but
the difference was not statistically significant (Table 2, p =
0.107). Joint effusion decreased by 8.8 12.3 ml (p <
0.05), but bony erosion, marrow edema and lymph nodes
showed no change (p > 0.1). Correlation between changes
in visual analog scale values and in MRI scores was not sig-
nificant (p > 0.01), but there was significant correlation be-
tween the former and changes in knee circumference (p <
0.05). Among MRI scores, changes in synovial volume
showed positive correlation with changes in synovial thick-
ness (p < 0.05) and the amount of effusion (p < 0.01).
Pre- and post-radiation synovectomy images indicated
that the lateral femur was the most frequent site of bony
erosion (score of 27), followed by the medial tibia (21.5),
medial femur (20.5), lateral tibia (7), tibio-fibular joint (6)
and patella (1). Bone marrow edema was observed most
frequently in the medial femur (15), medial tibia (9), lateral
femur (7.5), lateral tibia (5.5) and patella (2).
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Fig. 3. MR images of a 54-year-old
woman with rheumatoid arthritis of the
knee. 
A. Postcontrast, fat-suppressed, three-
dimensional spoiled gradient-echo sagit-
tal image (TR/TE=21.1/2.2, flip an-
gle=15 ) obtained before the intra-artic-
ular injection of 
166Ho-chitosan complex
depicts lymph nodes in the popliteal re-
gion (arrows). 
B. MR image obtained 4-months after
treatment shows that the size and num-
ber of the lymph nodes are unchanged
(arrows). 
AB
Table 2. MR Data Obtained Before and After Radiation Synovectomy
Patient  Synovial Volume  Synovial Thickness  Synovial Effusion  Baker Cyst  Bony Erosion  Bony Edema  Lymph Node 
No. (cm
3) (mm) (cm
3) (cm
3) (Score)  (Score) (Score)
T0 T1 T0 T1 T0 T1 T0 T1 T0 T1 T0 T1 T0 T1
01 69.1 60.1 4.3 4.4 12.8  9.0 0.3 0.2 4.0 4.5 1.0 0.5  1 1
02 83.1 71.9  3.7 3.6 74.4  51.0 2.9 1.8 2.0 2.5 2.0 1.5  1 1
03 40.4 58.3  3.4 3.6 36.9  15.2 1.0 1.0 0  0  1 0.5
04 99.5 70.5  4.7 4.6 42.3  25.1 5.5. 1.8 3.0 2.0 0  0  1 1
05 42.8 44.0  2.9 3.1 9.0 6.6 5.0 6.0 5.0 6.0  1 1
06 36.0 51.8  3.6 4.5 4.5  10.2 0.4 0.3 1.0 1.0 0 0  1 1
07 80.3 58.5  4.3 3.6 34.7  23.4 0.9 8.7 2.0 2.0 0  1.0  1  1
08 51.3 35.7  2.3 2.0 18.8  3.2 1.0 0.5 5.0 3.0  1 1
09 33.6 31.9  4.0 3.6 5.9 9.7 0  0 1.0 2.0  1 1
10 60.0 76.3  4.9 4.8 7.0  22.9 4.0 6.0 3.0 3.5  0 0
11 69.4 66.2  3.6 3.9 29.2  20.0 5.0 5.0 1.0 0.5  1 1
12 22.9 23.4  3.4 3.3 9.5 8.6 1.0 1.0 0  0  0 0
13 59.0 42.5  4.0 3.9 33.0  14.4 0.3 0.0 2.0 2.5 0  0  0 0
14 60.6 33.4  4.6 2.9 33.3  8.7 6.0 8.0 4.0 1.0  0 0
Mean 57.7 51.8 3.8 3.7 25.1  16.3 1.7 2.1 2.6 3.0 1.6 1.4 0.7 0.7
SD 21.5 16.8 0.7 0.8 19.5  12.1  2.1 3.3 1.9 2.5 1.9 1.8 0.5 0.5
p value 0.107 0.399 0.019 0.802 0.136 0.487 0.336
Note. T0: before treatment
T1: after treatment
SD: standard deviationTwenty-four hours after the injection of 
166Ho-CC, almost
all radioactivity was still retained in the knee joint ; less
than 1% had spread to other tissues. Eight days after injec-
tion, activity distribution rates had increased in the brain,
lungs, abdomen and pelvic area to 1.5%, 2.0%, 1.9%, and
1.9%, respectively. 
In this study, high intra- and inter-observer reproducibili-
ty were demonstrated. For observer A, mean percentage
average absolute variation was 0.5 (range, 0.16 2.1), and
the percentage coefficient of variation was 1.3% (0.1
1.8). Inter-observer mean percentage coefficient of varia-
tion was 0.5% (0.1 0.9).
DISCUSSION
Radiation Synovectomy
Radiation synovectomy is a locally acting treatment for
chronic refractory synovitis and is an alternative to intra-
articular injection of corticosteroids and other systemic
pharmacological treatments. Radionuclide treatment has
advantages over external radiotherapy: because most ra-
dionuclides currently used are beta emitters, which have
properties of high linear energy transfer and rapid fall-off,
there are no adverse effects on adjacent bones and soft tis-
sues.
An ideal radiation synovectomy agent should have the
following four characteristics (6, 25): first, the radionuclide
should have beta-particle energy sufficient to penetrate
and ablate the enlarged area of synovial tissue but not so
great as to damage underlying articular cartilage or overly-
ing skin. Any accompanying radiation should not generate
an unacceptable, extraneous dose. Second, the radionu-
clide should be attached to a particle that is sufficiently
small to be phagocytized but not so small as to leak from
the joint before being phagocytized; the appropriate size
range is usually thought to be 2 5  m. The binding be-
tween the radionuclide and particle should be irreversible
throughout the course of the radiotherapy; the timespan is
determined by the physical half-life of the particular iso-
tope employed. Third, the particle should be biodegrad-
able; persistence in the joint of non-biodegradable materi-
als can itself give rise to granulomatous tissues. Fourth, and
finally, any biologically induced degradation of the agent
should ideally release the radionuclide in a chemical form
that rapidly egresses from the body.
The accepted biological mechanism by which these
agents function involves their rapid phagocytosis by syn-
oviocytes, their even distribution over the surface of the
synovium, and the irradiation of pathologic synovial tissue. 
The primary disadvantage of this procedure is the unac-
ceptable radiation doses delivered to non-target organ sys-
tems due to leakage of radioactive material from the cavi-
ty. Leakage can, however, potentially be avoided in two
ways: by using large carrier particles or aggregates, and by
choosing a radioisotope that has a short half-life, thus al-
lowing almost all radioactivity to decay before leakage oc-
curs (25). 
166Ho-CC
166Ho-CC was initially introduced as an intratumoral ad-
ministration agent (7), and if injected locally into the liver
or a solid tumor, it precipitates, thus preventing systemic
distribution of 
166Ho. It is because chitosan dissolves in di-
lute mineral and organic acids, but precipitates at a pH of
above 6.0, that distribution does not occur (17). After we
administered 
166Ho-CC, radioactive concentrations in the
blood were low and cumulative urinary and fecal excre-
tions over a period of 0 72 hrs were 0.53% and 0.54%,
respectively. Suzuki et al. (7) has proved the suitability of
166Ho-CC for local injection by showing that 24 hours after
injection, less than 1% of the total injected amount was de-
tectable in tissues other than those at the injection site.
166Ho-CC leaks only minimally because in tissues it is trans-
formed into a gel, and has an appropriate half-life. In toxic-
ity evaluations after the intravenous injection of 
166Ho-CC,
the major effects of injections of 1 mCi/kg were limited to
the spleen, and the hematological parameters were re-
versible by day 14 (28). Our report is the first to describe
the MRI evaluation of DW-166HC radiation synovectomy
in patients with RA. Information regarding biodistribution,
doses, and adverse effects after intra-articular injection has
been detailed by Song et al. (27).
Several radionuclides are used for radiation synovecto-
my, namely 
90Y, 
32P, 
186Re, 
169Er, 
165Dy, and 
166Ho. Because of
the deep penetration capability of its energetic beta parti-
cles (mean tissue penetration of 3.6 mm), 
90Y has been
most commonly used to treat the rheumatoid knee, while
rhenium-186 and erbium-169 agents are also recommend-
ed for intermediate-sized joints (mean tissue penetration of
1.2 mm) and the smallest joints (mean tissue penetration of
0.3 mm), respectively (6). We believe that 
166Ho has sever-
al advantages over other radionuclides. First of all, it can
be produced in a simple way from 
165Ho, a naturally abun-
dant element, and is less expensive than 
90Y; second, be-
cause it can emit the gamma rays necessary for image ac-
quisition, it is also suitable for quantitative dosimetric stud-
ies ; third, it has a half-life of 26.8 hours; lastly, it has an
adequate penetration range for synovial ablation, while
avoiding damage to adjacent cartilage or bone. 
166Ho de-
posits ninety percent of its energy within an area 2.1 mm
in diameter, while the remainder is deposited within an
area measuring 2.1 8.7 mm (28). 
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ful radiation synovectomy has not been established. In
fact, the rationale for choosing a particular dose of a given
radionuclide in a given joint remains obscure, and most
published studies have relied on historically derived, em-
pirical dosimetry (28). In patients with RA, 
90Y is the most
commonly used agent for radiation synovectomy of the
knee, and the most commonly used dosage is 5 mCi.
Deutsch et al. (6) stated that at this dosage, 91% of pa-
tients showed a good response. 
90Y delivers an absorbed
dose (28 mGy/MBq) higher than that delivered by 
166Ho
(8.7 mGy/MBq) (29), and the therapeutic dosage of 
166Ho
must therefore be at least three times greater than that of
90Y. 
MR evaluation of responses to radiation synovectomy
In RA, the synovium becomes inflamed, and the synovial
mass consists of vascular congestion, edema and cellular in-
filtration as well as hyperplasia of the synovial lining and
pannus tissue formation (11, 30). The histologic changes
occurring after radiation synovectomy include the regres-
sion of destructive pannus, and the reduction of cellular in-
filtration and synovial sclerosis (31). The severity of the
disease might possibly be determined by measuring the
volume of synovial inflammation.
Several investigators have described the use of MRI for
quantification of the synovial volume of the knee joint (10,
11 13, 32). Although there is no consensus as to the opti-
mal MRI method for synovial volume measurement, we
used fat-suppressed, enhanced 3D SPGR imaging, which
has been previously described and permits a thin slice set-
ting and high tissue contrast between enhancing synovium
and non-enhancing tissue (8, 9, 33). Synovial volume mea-
surement has proven useful for evaluating the therapeutic
effectiveness of antirheumatic drugs (10, 12). Ostergaard et
al. (10) reported that the duration of clinical remission in
patients with RA showed significant inverse correlation to
pre-treatment synovial volume. They found that at relapse,
synovial volume had increased roughly to pretreatment
levels, but effusion volumes remained lower than before
treatment, and thus insisted that synovial volume measure-
ment could play a more important role in the assessment of
treatment outcome. 
Only one published report has described the usefulness
of synovial volume measurement after radiation synovec-
tomy (
90Y and triamcinolone) (11), noting that synovial vol-
ume tended to decrease, but not to a statistically significant
extent. Our results showed a similar tendency after treat-
ment with 
166Ho-CC, and the decrease was also statistically
insignificant.
As a means of evaluating the outcome of radiation syn-
ovectomy, investigators have used MR imaging to measure
synovial thickness (14, 34). Thickness was found to be re-
duced by 4.4 7.7 mm at one-year follow-up after 
165Dy
treatment (34), and by 1.0 2.3 mm at six-month follow-
up after 
90Y treatment (14). However, our results demon-
strated no significant change in synovial thickness, which
had decreased from 3.8 mm to 3.7 mm at follow-up four
months after treatment. We believe, however, that because
changes in synovial effusion may lessen the accuracy of
synovial thickness measurement, the measurement of syn-
ovial volume is a more reliable indicator. It is conceivable
that as synovial effusion decreases, proliferated synovial
tissue can become folded from an unfolded or effaced
state.
Joint effusion has been thought to be a therapeutic re-
sponse indicator (14); as measured by joint aspiration (14)
or MRI (10, 11), it has shown reductions after radiation
synovectomy ; good correlation was found between the as-
pirated volume of synovial fluid and the volume of fluid
calculated after MRI (11). In our study, the volume of effu-
sion measured by MRI was significantly lower after thera-
py, and, as was expected, correlated well with the circum-
ference of the knee, an indirect indicator of joint swelling.
On the other hand, the amount of fluid in Baker cysts
showed no significant change. We believe that therapeutic
effect may depend on communication between a Baker
cyst and the joint, though our study did not investigate
whether Baker cysts communicated with the knee joint.
Two common alterations occurring in the juxta-articular
bones in RA are osteoporosis and marginal erosion. The
latter usually develops near synovial pockets and on bare
areas that do not possess protective cartilaginous coats
(35), and may represent a very early manifestation of the
disease, occurring one or two years prior to the onset of
joint symptoms. In this study, the bony erosion score tend-
ed to increase even after radiation synovectomy, and for
this there are three possible reasons. One is that as ex-
plained by de Carvalho et al. (36), areas of bony erosion
may remain static for long periods of time or even become
bigger as more widespread osseous damage becomes mani-
fest. The second possible explanation is the fact that unless
erosive lesions communicate with the joint, intruded syn-
ovial tissue within the lesions cannot be reached by inject-
ed radiopharmaceuticals (37, 38). Finally, although the
amount of synovial tissue in an eroded area is reduced
over a given period, bone erosion may not be refilled with
bone or marrow tissue.
The occurrence of bone marrow edema has not been ful-
ly described, and the significance of its presence in RA has
been poorly investigated. In our study involving RA pa-
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other investigators have found it to be a rare manifestation
(39). This discrepancy may result from differences in the
duration of disease: in that earlier study, the mean duration
of knee synovitis was about ten weeks, whereas all synovi-
tis cases in our study were chronic. Bone marrow edema
was found most frequently in the medial femur, but bone
erosion had occurred in the lateral femur, a finding which
corroborates the fact that bone marrow edema is associat-
ed not only with bone erosion but also with conditions
such as periarticular osteoporosis, hyperemia, co-existing
osteoarthritis, and reflex sympathetic dystrophy superim-
posed on the rheumatoid process (35). It has been postulat-
ed in only one study that marrow edema reduction is asso-
ciated with remission after disease modifying anti-rheumat-
ic drug therapy (40); our results, however, showed that
bone marrow edema did not change significantly after radi-
ation synovectomy. We speculated that marrow edema re-
duction would ensue if synovial inflammation was re-
duced, but this did not occur during our follow-up period,
and for the evaluation of marrow edema in RA, further
study is thus required. 
Lymph nodes, which in this study occurred frequently in
the popliteal fossa, were rarely observed at MR imaging
for the evaluation of internal derangement of the knee. If
seen at MRI, they would have been abnormal. In this
study, lymph nodes showed no interval change after treat-
ment. Kojima et al. have reported the presence of reactive
proliferative lymph nodes in RA (41), describing histologi-
cal findings of follicular hyperplasia with active germinal
centers, and polyclonal plasma cell infiltration of the inter-
follicular area. The relationship between lymph node size
and disease activity is one that future studies should ad-
dress.
Certain investigators have reported the usefulness of MR
perfusion studies in the evaluation of RA, analysing syn-
ovial enhancement in terms of its degree and the maximal
gradient of increased signal intensity (11), the maximal en-
hancement ratio (14), the intensity of enhancement (34),
the time to maximum synovial lining signal ratio, and the
maximum synovial lining signal ratio (13). To determine
the usefulness of the quantification of synovial enhance-
ment, further investigation is required.
Our study suffers several limitations. One is that it is
cross-sectional, demonstrating clinical and MR imaging
changes occurring during a 4-month follow-up period after
166Ho-CC radiation synovectomy. There are no comparison
or control data. Other limitations are the small number of
patients and the short duration of follow-up. In the future,
long-term follow-up data should be collected from the
same patients, and a larger patient population should be
studied. From a technical point of view, MR contrast agent
may have leaked into a joint within the period of image ac-
quisition, affecting MRI measurements and perhaps leading
to the overestimation of synovial volume.
In conclusion, the decreased joint effusion observed at 4-
month follow-up resulted from radiation synovectomy of
the rheumatoid knee by means of intra-articular injection
of 
166Ho-CC. Changes in the volume of synovial enhance-
ment should be further followed up. 
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